Feb 01, 2023 / 11:30AM GMT
Operator
Ladies and gentlemen, good day, and welcome to Q3 FY '23 Earnings Conference Call of Alembic Pharmaceuticals Limited. We have with us today Mr. Pranav Amin, Managing Director; Mr. Shaunak Amin, Managing Director; Mr. R.K. Baheti, Director, Finance and CFO; Mr. Mitanshu Shah, Head of Finance; Mr. Jesal Shah, Head of Strategy; and Mr. Ajay Kumar Desai, Senior VP Finance. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. R.K. Baheti. Thank you, and over to you, sir.
Raj Kumar Shreeram Baheti - Alembic Pharmaceuticals Limited - Director of Finance, CFO & Executive Director
Thank you, Yashasvi. Good afternoon, everyone. Thank you all for joining the third quarter results conference call of Alembic Pharmaceuticals.
I'll start with the financials. During the quarter, our total revenue was up by 19% to INR 1,509 crores, EBITDA was INR 236 crores and net profit is INR 122 crores. EBITDA margin for the quarter was 16%. For 9 months FY '23, EBITDA was INR 476 crores and net profit was
Q3 2023 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Feb 01, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers